Captopril

Captopril
Clinical data
Pronunciation	/ˈkæptəprɪl/
Trade names	Capoten, others
AHFS/Drugs.com	Monograph
MedlinePlus	a682823
Pregnancy; category	AU: D;
Routes of; administration	By mouth
ATC code	C09AA01 (WHO) ;
Legal status
Legal status	EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	70–75%
Metabolism	Liver
Elimination half-life	1.9 hours
Excretion	Kidney
Identifiers
	IUPAC name (2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid;
CAS Number	62571-86-2 ;
PubChem CID	44093;
IUPHAR/BPS	5158;
DrugBank	DB01197 ;
ChemSpider	40130 ;
UNII	9G64RSX1XD;
KEGG	D00251 ;
ChEBI	CHEBI:3380 ;
ChEMBL	ChEMBL1560 ;
PDB ligand	X8Z (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID1037197 ;
ECHA InfoCard	100.057.806
Chemical and physical data
Formula	C9H15NO3S
Molar mass	217.28 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(O)[C@H]1N(C(=O)[C@H](C)CS)CCC1;
	InChI InChI=1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1 ; Key:FAKRSMQSSFJEIM-RQJHMYQMSA-N ;
	(verify)

Captopril, sold under the brand name Capoten among others, is an angiotensin-converting enzyme (ACE) inhibitor used for the treatment of hypertension and some types of congestive heart failure. Captopril was the first oral ACE inhibitor found for the treatment of hypertension.^[2] It does not cause fatigue as associated with beta-blockers.

Captopril was patented in 1976 and approved for medical use in 1980.^[3]

^ "List of nationally authorised medicinal products Active substance: captopril" (PDF). ema.europa.eu. European Medicines Agency. 26 November 2020. Archived from the original (PDF) on 31 October 2021.
^ Vidt DG, Bravo EL, Fouad FM (January 1982). "Medical intelligence drug therapy: captopril". The New England Journal of Medicine. 306 (4): 214–219. doi:10.1056/nejm198201283060405. PMID 7033784.
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 467. ISBN 978-3-527-60749-5.

[1] "List of nationally authorised medicinal products Active substance: captopril" (PDF). ema.europa.eu. European Medicines Agency. 26 November 2020. Archived from the original (PDF) on 31 October 2021.

[2] Vidt DG, Bravo EL, Fouad FM (January 1982). "Medical intelligence drug therapy: captopril". The New England Journal of Medicine. 306 (4): 214–219. doi:10.1056/nejm198201283060405. PMID 7033784.

[Fis2006-3] Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 467. ISBN 978-3-527-60749-5.

[1]

[2]

[3]